Literature DB >> 17000309

Aprotinin improves cerebral protection: evidence from a survival porcine model.

Vesa Anttila1, Ikuo Hagino, Yusuke Iwata, Bret A Mettler, Hart G W Lidov, David Zurakowski, Richard A Jonas.   

Abstract

OBJECTIVE: Aprotinin is a serine protease inhibitor used during cardiac surgery to reduce blood loss and preserve platelet function. It has also been shown to reduce leukocyte activation during and after cardiopulmonary bypass. The goal of the study was to test the hypothesis that aprotinin could reduce cerebral injury after low-flow cardiopulmonary bypass and deep hypothermic circulatory arrest.
METHODS: Sixteen piglets (mean weight, 13.6 +/- 1.3 kg) were randomly assigned to receive aprotinin or placebo (8 animals per group) before a 120-minute period of deep hypothermic circulatory arrest (15 degrees C) or 25 mL x kg(-1) x min(-1) low-flow cardiopulmonary bypass (25 degrees C or 34 degrees C). Piglets had a cranial window placed over the parietal cerebral cortex for direct examination of the microcirculation by means of intravital microscopy. Rhodamine-stained leukocytes were observed in postcapillary venules, with analysis for adhesion and rolling. Plasma was labeled with fluorescein isothiocyanate-dextran for assessment of functional capillary density. Neurologic and histologic scores were used as the primary outcome measures.
RESULTS: During rewarming, the mean number of both rolling and adherent leukocytes was significantly lower after aprotinin administration (P < .05). At 5 and 15 minutes of rewarming, functional capillary density recovered faster with aprotinin treatment (P < .05). Functional outcome (neurologic deficit score) on postoperative day 1 was significantly improved in aprotinin-treated piglets (P < .05).
CONCLUSIONS: Aprotinin reduces inflammation and improves neurologic outcome after a prolonged period of deep hypothermic circulatory arrest or low-flow cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17000309     DOI: 10.1016/j.jtcvs.2006.06.017

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  10 in total

1.  Hypothermic circulatory arrest increases permeability of the blood brain barrier in watershed areas.

Authors:  Toru Okamura; Nobuyuki Ishibashi; T Susheel Kumar; David Zurakowski; Yusuke Iwata; Hart G W Lidov; Richard A Jonas
Journal:  Ann Thorac Surg       Date:  2010-12       Impact factor: 4.330

Review 2.  Pharmacologic strategies for combating the inflammatory response.

Authors:  Clive Landis
Journal:  J Extra Corpor Technol       Date:  2007-12

Review 3.  Is there still a role for aprotinin in cardiac surgery?

Authors:  Neel R Sodha; Munir Boodhwani; Frank W Sellke
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  Differential neuronal vulnerability varies according to specific cardiopulmonary bypass insult in a porcine survival model.

Authors:  Nobuyuki Ishibashi; Yusuke Iwata; Toru Okamura; David Zurakowski; Hart G W Lidov; Richard A Jonas
Journal:  J Thorac Cardiovasc Surg       Date:  2010-12       Impact factor: 5.209

5.  Aprotinin, but not ε-aminocaproic acid and tranexamic acid, exerts neuroprotection against excitotoxic injury in an in vitro neuronal cell culture model.

Authors:  Zhaohui Lu; Ludmila Korotcova; Akira Murata; Nobuyuki Ishibashi; Richard A Jonas
Journal:  J Thorac Cardiovasc Surg       Date:  2013-11-13       Impact factor: 5.209

6.  Aprotinin concentration varies significantly according to cardiopulmonary bypass conditions.

Authors:  T Okamura; N Ishibashi; Y Iwata; D Zurakowski; R A Jonas
Journal:  Perfusion       Date:  2008-11       Impact factor: 1.972

7.  Aprotinin protects the cerebral microcirculation during cardiopulmonary bypass.

Authors:  N Ishibashi; Y Iwata; D Zurakowski; H G W Lidov; R A Jonas
Journal:  Perfusion       Date:  2009-03       Impact factor: 1.972

8.  Optimal dose of aprotinin for neuroprotection and renal function in a piglet survival model.

Authors:  Yusuke Iwata; Toru Okamura; Nobuyuki Ishibashi; David Zurakowski; Hart G W Lidov; Richard A Jonas
Journal:  J Thorac Cardiovasc Surg       Date:  2009-04-21       Impact factor: 5.209

9.  Plasmin Activation of Glial Cells through Protease-Activated Receptor 1.

Authors:  André R Greenidge; Kiana R Hall; Ian R Hambleton; Richelle Thomas; Dougald M Monroe; R Clive Landis
Journal:  Patholog Res Int       Date:  2013-01-28

10.  Role of the Toll‑like receptor 3 signaling pathway in the neuroprotective effect of sevoflurane pre‑conditioning during cardiopulmonary bypass in rats.

Authors:  Jin Zhou; Nan Zhou; Xiao-Ning Wu; Hui-Juan Cao; Ying-Jie Sun; Tie-Zheng Zhang; Ke-Yan Chen; Dong-Mei Yu
Journal:  Mol Med Rep       Date:  2015-10-09       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.